Exelixis Hits Blockbuster Status

Sales of Exelixis' (NASDAQ: EXEL) cabozantinib franchise, which includes Cabometyx for kidney and liver cancers and Cometriq for thyroid cancer, broke $250 million globally in the second quarter, making the drug a blockbuster, typically defined as $1 billion in annual sales.

Metric

Q2 2019

Continue reading

Quelle Fool.com